|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.98 USD | -4.60% |
|
-5.46% | +40.18% |
| 06-29 | Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark | CI |
| 06-29 | Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index | CI |
Company Valuation: Monte Rosa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 949.7 | 368.3 | 282.8 | 426.4 | 1,021 | 1,857 | - | - |
| Change | - | -61.22% | -23.21% | 50.74% | 139.48% | 81.86% | - | - |
| Enterprise Value (EV) | 603.6 | 105.5 | 50.43 | 54.22 | 1,021 | 1,857 | 1,857 | 1,857 |
| Change | - | -82.52% | -52.19% | 7.5% | 1,783.24% | 81.86% | 0% | 0% |
| P/E | -6.9x | -3.31x | -2.15x | -7.08x | -34.1x | -13.3x | -12x | -9.58x |
| PBR | 2.75x | 1.32x | 1.58x | 1.91x | - | - | - | - |
| PEG | - | 0.1x | -0.1x | 0.1x | 0.6x | -0x | -1.1x | -0.4x |
| Capitalization / Revenue | - | - | - | 5.64x | 8.26x | 41.7x | 31.9x | 104x |
| EV / Revenue | - | - | - | 0x | 0x | 41.7x | 31.9x | 104x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -9.94x | -8.9x | -6.76x |
| EV / FCF | -0x | -0x | -0x | 0x | -0x | 619x | -68.8x | 299x |
| FCF Yield | -7.28% | -28.6% | -22.2% | 8.91% | -2.69% | 0.16% | -1.45% | 0.33% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.96 | -2.3 | -2.63 | -0.98 | -0.46 | -1.656 | -1.836 | -2.294 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 75.62 | 123.7 | 44.48 | 58.17 | 17.8 |
| EBITDA | -70.75 | -108.6 | -137.1 | -72.99 | - | - | - | - |
| EBIT 1 | -72.88 | -112.4 | -143.3 | -81.11 | -54.21 | -186.9 | -208.7 | -274.8 |
| Net income 1 | -73.96 | -108.5 | -135.4 | -72.7 | -38.63 | -167.3 | -193.5 | -260.3 |
| Net Debt | -346.1 | -262.8 | -232.4 | -372.1 | - | - | - | - |
| Reference price 2 | 20.42 | 7.61 | 5.65 | 6.94 | 15.68 | 21.98 | 21.98 | 21.98 |
| Nbr of stocks (in thousands) | 46,506 | 48,399 | 50,062 | 61,436 | 65,118 | 84,479 | - | - |
| Announcement Date | 29/03/22 | 16/03/23 | 14/03/24 | 20/03/25 | 17/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -13.92x | - | - | - | 1.95B | |
| 35.38x | 6.18x | 19.12x | 0.93% | 50.73B | |
| -23.4x | 342.07x | -22.1x | -.--% | 39.73B | |
| 25.29x | 2.8x | 12.09x | -.--% | 34.69B | |
| 45.73x | 4.5x | 28.9x | -.--% | 33.21B | |
| 27.05x | 7.93x | 19.91x | 0.42% | 26.76B | |
| 31.75x | 5.12x | 23.32x | -.--% | 15.37B | |
| 23.95x | 2.04x | 8.96x | 1.12% | 13.78B | |
| 23.74x | 1.89x | 11.45x | -.--% | 12.85B | |
| Average | 19.51x | 46.57x | 12.71x | 0.31% | 25.45B | |
| Weighted average by Cap. | 22.18x | 63.82x | 11.59x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- GLUE Stock
- Valuation Monte Rosa Therapeutics, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
